Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Puterizumab and SBRT in NSCLC with Intrapulmonary Metastasis
NCT06434740Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in non-small cell lung cancer (NSCLC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Tumor Response Rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06434740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434740.